Hi-Tech Pharmacal Acquires Nystatin Oral Suspension ANDA

Hi-Tech Pharmacal Co., Inc. HITK announced that it has acquired the rights to the Abbreviated New Drug Application (ANDA) for Nystatin Oral suspension from Bausch + Lomb, the global eye health company for an undisclosed upfront payment and a future royalty. Nystatin oral suspension is indicated for the treatment of candidiasis in the oral cavity. The market for Nystatin oral solution was $23 million based on IMS data. Hi-Tech intends to launch Nystatin oral solution in all commercially available fill sizes as soon as it satisfies all applicable FDA requirements.